Zobrazeno 1 - 10 of 35 pro vyhledávání: '"James S Hu"'
3
Physician Burnout-Evidence That Leadership Behaviors Make a Difference: A Cross-Sectional Survey of an Academic Medical Center
Autor: James S Hu, Jennifer Phillips, Choo Phei Wee, Louis N Pangaro
Publikováno v: Military medicine.
Introduction High rates of physician burnout are well documented in the USA. Identifying beneficial leadership behaviors as an organizational approach to mitigating burnout can lead to improved wellness in the physicians that they lead; however, few
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211b52ebac9bddc2e4f3a765d3e0ce20
https://pubmed.ncbi.nlm.nih.gov/36260483
Zobrazit plný text záznamu
4
Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature
Autor: Steven N. Luminais, Xiao T. Chen, Darwin Roman, Brian Ma, Alexander B. Christ, James S. Hu
Publikováno v: Journal of Medical Case Reports. 16
Background Tumor lysis syndrome is an oncologic emergency that involves multiple metabolic abnormalities and clinical symptoms such as acute renal failure, cardiac arrhythmias, seizures, and multiorgan failure, and may be fatal if not promptly recogn
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31920568fb7ab28cbbabaffa840981bf
https://doi.org/10.1186/s13256-022-03469-6
Zobrazit plný text záznamu
5
Predictors of readmission after craniotomy for meningioma resection: a nationwide readmission database analysis
Autor: Michelle Lin, Steven L. Giannotta, Elliott A Orloff, Li Ding, William J. Mack, Frank J. Attenello, James S. Hu, Elliot Min, Kerolos S R Youssef
Publikováno v: Acta Neurochirurgica. 162:2637-2646
Meningiomas are the most common benign primary brain tumors. The mainstay of treatment, surgical resection, is often curative. Given the excellent prognosis of these lesions, minimizing perioperative complications is of the utmost importance. With th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b103b54b7d089cb88f586db77c9909
https://doi.org/10.1007/s00701-020-04528-x
Zobrazit plný text záznamu
7
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Autor: Hong Wang, Antonio López Pousa, Silvia Stacchiotti, Anna M. Szpurka, Andrew S. Brohl, Benjamin C. Powers, Gerard J. Oakley, Brian A. Van Tine, Gary Mo, Donna E. Levy, James S. Hu, Javier Martin-Broto, Robin L. Jones, Jean-Yves Blay, Matteo Ceccarelli
Publikováno v: MOLECULAR CANCER THERAPEUTICS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Digital.CSIC. Repositorio Institucional del CSIC
This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated with olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six cyc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de5badae0ceef3db00d6fe9bfd1a530
https://pubmed.ncbi.nlm.nih.gov/33177152
Zobrazit plný text záznamu
8
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer
Autor: Primo N. Lara, Amol Rao, Sumanta K. Pal, Mayer Fishman, Jacek K. Pinksi, James S. Hu, Walter M. Stadler, Tanya B. Dorff, Ulka N. Vaishampayan, David I. Quinn, Jeff Longmate
Publikováno v: Cancer. 123:4566-4573
BACKGROUND Targeting the vascular endothelial growth factor (VEGF) pathway has improved outcomes in metastatic renal cell carcinoma (RCC); however, resistance inevitably occurs. CD105 (endoglin) is an angiogenic pathway that is strongly upregulated a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2176e1a12626e11f298a35a2f8a749e
https://doi.org/10.1002/cncr.30942
Zobrazit plný text záznamu
9
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
Autor: William W. Tseng, Gino K. In, James S. Hu
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Therapeutic Advances in Medical Oncology
Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylatin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d2dd59b2fda40eecb1374866e9641c
https://doi.org/10.1177/1758834017712963
Zobrazit plný text záznamu
10
Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
Autor: James S. Hu, Arjun Mehta, George R. Matcuk, Kristi M. Lara, Gino K. In
Publikováno v: JAAD Case Reports
Merkel cell carcinoma (MCC) is an aggressive, neuroendocrine carcinoma of the skin with an incidence of 2,000 cases per year, and a 5-year survival rate of 30% to 64%.1 Risk factors for MCC include advanced age, fair skin, and immunosuppression, incl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b452bddf7f7219a73312fe82677eaf69
http://europepmc.org/articles/PMC6226586
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje